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INTRODUCTION 
Mid trimester termination of pregnancy is one of the controversial 
issues in obstetrics and gynecology which has moral, technical, 
emotional and social issues. Many Indian women opt for MTP (Medical 
Termination of Pregnancy) in second trimester inspite of increased 
morbidity like excessive hemorrhage, uterine perforation and infection 
because of unplanned pregnancies. In addition, there is a continuous 
need for termination of pregnancy in second trimester as there are 
advanced antenatal diagnostic tests which enable us to identify lethal 
fetal anomalies. 
Termination of pregnancy in second trimester is associated with 
much more morbidity and mortality than when it is done in the first 
trimester. The various methods for second trimester termination of 
pregnancy are still under scrutiny and the search for the ideal method 
which is the safest, easiest, cheapest and optimally most effective is still 
going on. 
Second trimester pregnancy termination can be carried out by 
both medical and surgical methods. Medical methods are comparatively 
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safer and have superseded the surgical methods because of risks 
involved in surgical methods. 
The various drugs used for bringing about induction of abortion 
have undergone tremendous change. From instillation of intra-amniotic 
hypertonic saline, urea and then to extra-amniotic ethacridine lactate and 
now to prostaglandin analogues, the entire scenario is undergoing a 
metamorphosis. 
The Prostaglandin analogue misoprostol introduced in the late 
1970’s was cheap and stable at room temperature. It has the ability of 
being administered by any route (Vaginal/Oral/Buccal/Sublingual). 
Hence Misoprostol is being extensively evaluated for being used in 
second trimester abortion. 
The subsequent introduction of anti progestin ,mifepristone in 
1980 has shortened the induction abortion interval and reduced the 
dosage of misoprostol required though the cost is high. 
The present study was undertaken to evaluate the efficacy of 
Mifepristone and vaginal misoprostol combination with vaginal 
misoprostol alone in the termination of second trimester pregnancy. 
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REVIEW OF LITERATURE 
The unmet need of safe abortion among women with unwanted 
pregnancy continues to be a major obstetric challenge in the efforts to 
provide better health care to an increasing number of women currently 
subject to repeated unsafe abortions. The estimated maternal deaths 
directly due to consequences of unsafe abortions amounts to 300 - 500 
per day1. 
MTP ACT 
Medical termination of pregnancy (MTP) under supervision is an 
important way to reduce the mortality due to septic abortions. Although 
MTP has been legalised in India (MTP Act, 1971), the incidence of 
unsafe septic induced abortions has not decreased. Septic abortion is a 
significant health problem with short and long term complications that 
affect the quality of life. Both spontaneous and induced abortion can 
result in septic complications, with the latter disproportionately higher. 
MTP Act was introduced with the aim of reducing these unsafe 
and subsequent septic abortions. The MTP Act was passed in the Indian 
parliament in 1971 and came into force in 1972.  
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THE LAW SPECIFIES 
1. Grounds for performing MTP:  
a. Medical    b. Eugenic  
c. Humanitarian   d. social 
2. Persons who can perform MTP: 
Only a registered medical practitioner having postgraduate 
training or qualification in obstetrics and gynaecology in a specialized 
and recognized training centre for MTP can perform the procedure. 
3. Place where MTP can be performed:  
     MTP can be performed only in: 
a. A hospital established and maintained by the government. 
b. A place recognized and approved by the government under 
this act. 
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METHODS OF MEDICAL TERMINATION OF PREGNANCY 
(MTP): 
MTP can be performed either in the first or second trimester by 
either surgical or medical means. An ideal method would be one which 
is safe, quick, 100% effective, inexpensive and without any immediate 
or late side effects. Since no ideal method is available at present we have 
to choose a method that is effective with minimal side effects and 
complications. 
FIRST TRIMESTER: 
The two modes of termination of first trimester pregnancy are 
medical and surgical2. 
MEDICAL 
•  Mifepristone ,Misoprostol, Gemeprost 
SURGICAL 
•  Menstrual regulation, Manual vacuum aspiration, Suction 
evacuation 
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SECOND TRIMESTER 
Termination of second trimester pregnancy can be done by either 
medical or surgical means. Majority are performed medically to reduce 
the incidence of complications associated with surgical methods like 
hemorrhage, Pelvic infections, uterine and cervical injuries.  
 
MEDICAL 
 INTRA AMNIOTIC INSTILLATION  
 Hypertonic solutions , 20% saline ,30% urea, 
15-methylPGF2 α 
Complications with hypertonic saline include hemorrhage, 
infection, hypernatremia and coagulation disorders. Hence, hypertonic 
saline is not used for induction of abortion in recent times3. 
 EXTRA AMNIOTIC INSTILLATION 
  Ethacridine lactate , PGF2α 
 SYSTEMIC 
 ORAL 
  Mifepristone, Misoprostol.   
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 INTRA MUSCULAR 
  PGF2α 
 VAGINAL  
   Prostaglandins-PGE1, PGE2  
 INTRAVENOUS 
   High dose oxytocin  
 SURGICAL  
Aspirotomy ,Hysterotomy ,Hysterectomy 2 
DRUGS USED IN SECOND TRIMESTER PREGNANCY 
TERMINATION: PROSTAGLANDINS: 
Prostaglandins, oxygenated metabolites Of C20 carboxylic acid, 
are naturally found in most biological tissues where they act as 
modulators of cell function. They act through receptors of G-protein 
family that are coupled to a variety of intracellular signal mechanisms. 
Believing that the active principle originated in the prostate, von Euler 
coined the term PROSTAGLANDINS. Prostaglandins of E and F family 
can produce uterine contractions at any period of gestation. 
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CHEMISTRY: 
Prostaglandins are a family of polyunsaturated 20-carbon fatty 
acids containing a cyclopentane ring and two aliphatic side chains. 
Chemically they are derivatives of the hypothetical prostanoic acid. 
Prostaglandins are divided into groups (A, B, C, D, E, F, G, H, I) 
according to differences in the structure of the five membered 
cyclopentane ring4. Sune K Bergstrom, Bengt I Samuelsson and John R 
Vane jointly received  Nobel Prize (1982) in Physiology or Medicine for 
their research on prostaglandins5. 
BIOSYNTHESIS5: 
 
 
 
 
 
FIG 1: BIOSYNTHESIS OF PROSTAGLANDINS 
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Prostaglandins are derived from arachidonic acid present in 
membrane phospholipids. On its release from membrane phospholipids 
in response to cellular signals, arachidonic acid is acted upon by two 
types of enzymes - 
• Cyclo-Oxygenase which leads to prostaglandin formation, 
which are compounds with ring structure. 
• Lipo-Oxygenase which leads to leukotriene formation, 
which are compounds with open chain structure. 
Natural prostaglandins are unstable compounds, lack specificity 
and are poorly tolerated. The advent of synthetic prostaglandins like 
misoprostol has greatly evaded these disadvantages. 
MISOPROSTOL 
Misoprostol is a prostaglandin El analogue and has been licensed 
for treatment and prevention of NSAID-associated gastro-duodenal 
ulcers. It has been available in 200 mcg and 100 mcg tablets in the 
market since 1985 in more than 87 countries under the trade name 
Cytotec® manufactured by SEARLE6 (now Pfizer),but other brand 
name and Generic formulations are now available as well. 
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There are several reasons that make misoprostol a unique drug in 
the market. It binds selectively to EP2/EP3 receptors, which makes it a 
potent uterotonic agent without affecting the bronchi or blood vessels. 
This effect has made misoprostol very beneficial and a widely used drug 
for several indications within reproductive health such as postpartum 
hemorrhage, labour induction, missed abortion, intrauterine foetal death, 
induced abortion and cervical ripening prior to curettage. Prostaglandins 
like misoprostol have two important modes of action in the female 
reproductive system; they induce the ripening of the uterine cervix and 
stimulate uterine contractions. 
 
 
 
FIG 2: COMMERCIAL PREPARATION OF MISOPROSTOL 
Other advantages of misoprostol are that it is very cheap 
compared to other prostaglandins available in the market, it can be 
stored at room temperature for years, it can be administered orally, 
sublingually, rectally and vaginally and it has no severe side effects 
apart from those related to its uterotonic effects. All these attributes 
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make misoprostol very suitable for use in settings with limited 
resources. 
 
FIG 3: AVAILABILITY & APPROVAL STATUS OF 
MISOPROSTOL WORLD WIDE 
CHEMISTRY 
 Misoprostol is a 15-deoxy-16-hydroxy-16-methyl synthetic 
analog of prostaglandin E1 and is a water soluble viscous gel. The 
commercial preparation usually contains inactive ingredients 
hydrogenated castor oil hydroxyl-propyl methyl cellulose, micro 
crystalline cellulose and sodium starch glycolate6 
 
 
FIG 4: STRUCTURE OF MISOPROSTOL 
 
FIG 5 : STEREOTACTIC 
CONFIGURATION OF MISOPROSTOL 
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PHARMACOKINETICS 
The half life of misoprostol is 20-40 minutes and plasma 
concentrations peak in approximately 30 minutes and decline rapidly 
thereafter. It is metabolized by the fatty acid oxidation processes that 
take place in numerous organs in the body, primarily the liver and less 
than 1 percent of its active metabolite is excreted in the urine. 
Misoprostol has no known drug interactions nor does it induce the 
hepatic cytochrome P-450 enzyme system. 
After oral administration, misoprostol is rapidly absorbed and 
converted to its pharmacologically active metabolite misoprostol acid. 
The bioavailability of misoprostol is decreased by concomitant intake of 
food or antacids7. 
ROUTES OF ADMINISTRATION 
Many studies comparing the efficacy of the different routes of 
administration of misoprostol have been carried out. There is still no 
consensus on what is the most effective route of administration or 
dosage. Most studied routes of administration are oral and vaginal. It 
was shown that the systemic bioavailability, measured as the Area 
Under Curve, was higher after vaginal misoprostol than after oral 
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misoprostol. It is faster absorbed orally than vaginally with higher peak 
serum level, but vaginally absorbed levels are more prolonged.  
Since misoprostol is only approved for oral administration and 
most women prefer to take the tablets orally, this route of administration 
seems to be the most convenient but high doses have a greater risk of 
causing uterine hyperstimulation. Vaginal use of lower doses seems to 
be associated with less uterine hyperstimulation, less side effects and a 
higher efficacy rate in inducing medical abortion. 
There have also been recent studies on buccal administration of 
misoprostol where it was found to be effective for cervical ripening in 
labour induction but also resulted in a higher incidence of tachysystole 
compared to the intravaginal route of administration7. 
(Error bars represent 1 standard deviation.)  
FIG6: MEAN PLASMA CONCENTRATIONS OF 
MISOPROSTOL ACID OVER TIME WITH ORAL, RECTAL, 
AND  VAGINAL ADMINISTRATION 
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ADVERSE REACTIONS 
The most common adverse effects of misoprostol are nausea, 
vomiting, diarrhoea, abdominal pain, chills, shivering and fever all of 
which are dose dependent7. Both PGE2 and PGF2α can cause myocardial 
infarction and bronchospasm but this has not been observed with 
misoprostol.   
TERATOGENICITY 
Mobius syndrome (congenital facial palsy) and limb defects have 
occurred in infants of women who have taken misoprostol in the first 
trimester in an unsuccessful attempt to induce abortion. There was also 
an increased incidence of transverse limb defects, ring shaped 
constrictions of extremities, arthrogryposis, hydrocephalus, 
holoprosencephaly and exstrophy of bladder7.  
USES IN OBSTETRICS 
MISOPROSTOL IN FIRST TRIMESTER 
1. Medical Abortion 
 For first trimester abortions, misoprostol is used extensively with 
either mifepristone or methotrexate.  
2. 
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Mifepristone is a synthetic steroid compound used as a 
pharmaceutical abortifacient. It is used as an abortifacient in the first 
two months of pregnancy, and in smaller doses as an emergency 
contraceptive. During early trials it was known as RU-486, its 
designation at the Roussel Uclaf company, which designed the drug. 
The drug was initially made available in France and other countries then 
followed often amid controversy. In France and countries other than the 
United States it is marketed and distributed by Exeigyn Laboratories 
under the tradename Mifegyne. In the United States it is sold by Danco 
Laboratories under the tradename Mifeprex. (The drug is still commonly 
referred to as "RU-486")5. 
FIG-9 COMMERCIAL PREPARATION OF MIFEPRESTONE 
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FIG 10 MIFEPRESTONE AVAILABILITY 
 
PHARMACOLOGY 
Mifepristone is a 19-nor steroid with a bulky p-dimethylamino 
phenyl substituent above the plane of the molecule at the 11 β position 
responsible for inducing or stabilizing an inactive receptor conformation 
and a hydrophobic 1propynyl substituent above the plane of the 
molecule at the 17α-position that increases its progesterone receptor 
binding affinity. In the presence of progesterone, mifepristone acts as a 
competitive receptor antagonist at the progesterone receptor (in the 
absence of progesterone, mifepristone acts as a partial agonist). 
In addition to being an antiprogestogen, mifepristone is also an 
antiglucocorticoid and a weak antiandrogen. Mifepristone's relative 
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binding affinity at the progesterone receptor is more than twice that of 
progesterone. Its relative binding affinity at the glucocorticoid receptor 
is three times more than that of dexamethasone and ten times more than 
that of cortisol, its relative binding affinity at the androgen receptor is 
less than one third that of testosterone. It does not bind to the oestrogen 
or mineralocorticoid receptors. 
Mifepristone as a regular contraceptive at 2 mg daily prevents 
ovulation (11 mg daily does not). A single preovulatory 10 mg dose of 
mifepristone delays ovulation by 3 to 4 days and an emergency 
contraceptive as a single 1.5 mg dose of the progestin levonorgestrel. In 
women, mifepristone at doses greater or equal to 1 mg/kg antagonizes 
the endometrial and myometrial effects of progesterone. In humans, an 
antiglucocorticoid effect of mifepristone is manifested at doses greater 
than or equal to 4.5 mg/kg by a compensatory increase in ACTH and 
cortisol. In animals, a weak antiandrogenic effect is seen with prolonged 
administration of very high doses of 10 to 100 mg/kg. 
In medical abortion regimens, mifepristone blockade of 
progesterone receptors directly causes endometrial decidual 
degeneration, cervical softening and dilatation, release of endogenous 
prostaglandins and an increase in the sensitivity of the myometrium to 
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the contractile effects of prostaglandins. Indeed mifepristone 
administration gradually elicits a 5 fold increase in sensitivity to PG 24-
48 hrs after its administration. 
In women undergoing 2nd trimester abortion, a single100 mg oral 
dose produced fetal cord blood concentrations of mifepristone ranging 
from 20 ng/ml{30 minutes} to 400 ng/ml{18 hours}. The peak maternal 
concentration {1500 ng/ml} was attained in 12 hours and the average 
fetal : maternal ratio was approximately 0.33. An active transport 
mechanism was suggested because of the fetal concentration increase  
exponentially8.  
When followed sequentially by a prostaglandin, mifepristone in a 
dose of 200 mg is as effective as 600 mg in producing a medical 
abortion9,10. 
PHARMACOKINETICS : 
The half life of mifepristone is 18 hrs. Bio availability is 64%. It 
is metabolized in liver and mainly excreted through feces (83%) and 
renal(9%). 
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Adverse Effects : 
Neonatal exposure to a single large dose of mifepristone in rats 
were not associated with any reproductive problems, although chronic 
low-dose exposure of newborn rats to mifepristone was associated with 
structural and functional reproductive abnormalities. 
Teratology studies in mice, rats and rabbits revealed 
teratogenicity for rabbits, but not rats or mice. The rate of birth defects 
in human infants exposed in utero to mifepristone and misoprostol is 
very low, and may be due to misoprostol alone. 
CONTRAINDICATIONS : 
In the presence of an intrauterine device (IUD) ,Ectopic 
pregnancy, Adrenal failure, Hemorrhagic disorders, Inherited porphriya, 
and Anticoagulant or long-term corticosteroid therapy. 
OTHER USES 
Regular long term use as an oral contraceptive, and treatment of: 
Uterine fibroids, endometriosis, major depression with psychotic 
features, glaucoma, meningiomas, breast cancer, ovarian cancer, 
prostate cancer, and some types of Cushing’s syndrome. 
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VARIOUS STUDIES OF MISOPROSTOL 
Route of Administration:  
Vaginal versus Oral:  
Bebbington et al11 compared two protocols for the use of 
misoprostol in mid trimester pregnancy termination - oral vs vaginal ,14 
women were included in the study. They were randomly assigned to 
receive misoprostol 200 mcg vaginally every hour for three hours 
followed by 400 mcg every four hours orally or vaginally. Induction to 
abortion interval was significantly shorter in the vaginal group (14.5 
hours) than in the oral group (19.6 hours). Febrile morbidity was higher 
in the vaginal group (25%) vs oral group (6.7%) but this subsided 
without any specific treatment. 
Sublingual versus Vaginal:  
Tang et a112 compared sublingual or vaginal misoprostol 400 
mcg every three hours for a maximum of five doses in second trimester 
abortion. They concluded that the use of vaginal misoprostol resulted in 
a higher success rate of 85% than sublingual misoprostol of 64% at 24 
hours but the abortion rates were similar at 48 hours. 
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Sublingual versus Oral versus Vaginal: 
A study by Aronsson et al13 (2004) reported on the effect of 
misoprostol on uterine contractility following different routes of 
administration (sublingual, vaginal and oral). The study showed that the 
increase in uterine activity 24h after administration and thereafter was 
similar for both the sublingual and vaginal groups. These findings 
suggest that sublingual administration results in a more rapid effect on 
uterine contractility and may explain the higher requirement for 
intramuscular opiates.  
Interval of Administration 
Jain et al14 randomized One hundred pregnant women between 
12-22 weeks gestation to receive 200 mcg of misoprostol intravaginally 
either every 6hrs  or every 12 hrs for up to 48 hours. The incidences of 
abortion within 48 hours after initial drug administration were 87.2% 
and 89.2% , the mean abortion intervals 13.8 hrs and 14.0 hrs in the 6hrs 
and 12hrs group respectively. Side effects were similar between the two 
groups. They concluded that misoprostol administered vaginally is 
effective for terminating second-trimester pregnancies and that 
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shortening the dosing interval from 12 to 6 hours produced no 
significant benefit. 
Comparison of dosage /Dosage Administration 
Herabutya et al15 randomized One hundred and forty three 
pregnant women between 14-26 weeks gestation into 2 groups to receive 
either 600mcg or 800mcg of intravaginal misoprostol every 12 hours 
until abortion was induced The incidences of abortion within 24 hours 
after initial drug administration were 82.1% and 78.9%, within 48 hours 
92.5% and 92.1% , the mean abortion intervals were 15.2 hours and 15.3 
hours, the complete abortion rates 77.6%  and 72.4% , and body 
temperature of more than 380 C was noted in 26.9% and 71.1% ( p < 
0.001) in the 600 and 800 mcg group, respectively. All other side-effects 
were similar between the two groups. They concluded that considering 
the effectiveness and febrile complications, 600 mcg applied every 12 
hours is the most appropriate dose for second trimester termination. 
Ramsey et a116 evaluated the cardiovascular effects of high dose 
vaginal misoprostol 600 mcg by trans thoracic electrical bioimpedance 
monitoring concluded that high dose vaginal misoprostol does not alter 
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maternal cardiac function but further clinical data is needed to validate 
these findings in view of small sample size. 
In a study on Ramin KD, Ogburn PL, Danilenko DR, Ramsey 
PS17  reviewed the experience with high-dose oral misoprostol for mid-
trimester pregnancy interruption Patients received 400 mcg misoprostol 
orally every 4 h. Women undelivered within 24 h were considered 
failures and were treated with high-dose oxytocin. For comparison, a 
group of women treated with high-dose oxytocin were evaluated. 
Induction-to-delivery interval  was significantly shorter in the 
misoprostol cohort (15.2 hrs) compared with those treated with oxytocin 
(21.7 hrs). Misoprostol group delivered within 24 h (91.0%) compared 
with the oxytocin group (62.0%; p = 0.04). Adverse outcomes and side 
effects were not significantly different between the study groups. 
 High-dose oral misoprostol is more effective than concentrated 
oxytocin infusion for mid-trimester pregnancy interruption. 
Comparison of Misoprostol with other methods                         
In a study by Chauduri et al18 compared extraamniotic instillation of 
ethacridine lactate with vaginal misoprostol in second trimester 
abortion. 
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The mean interval from induction to abortion was shorter in 
misoprostol group (15.5 hrs vs 31.3 hrs). The rate of complete abortion 
was 66.6% for misoprostol and 70% for ethacridine lactate. Side effects 
were uncommon and did not differ between the two groups. They 
concluded that the success rates of misoprostol and ethacridine lactate 
were comparable but the induction abortion interval was almost half in 
misoprostol group when compared with that in ethacridine lactate group. 
Yapar et al19 compared the efficacy of five different methods for 
second trimester pregnancy termination between 14 and 28 weeks 
gestation. Three hundred and forty patients with poor cervical condition 
(Bishop score : < 4) were subjected to one of five termination methods 
were subsequently assessed: (i) extra amniotic administration of 
ethacridine lactate (82 patients) (ii) intracervical prostaglandin PGE2 gel 
(100 patients) (iii) intravenous infusion of concentrated oxytocin (36 
patients) (iv) vaginal misoprostol (49 patients) and (v) balloon insertion 
(73 patients). They concluded that in comparison with the five methods, 
the use of extraamniotic ethacridine, intravenous concentrated oxytocin, 
and balloon was found to provide more effective treatment than 
intracervical PGE2 and misoprostol in terms of achievement of abortion 
within 24 and 48 h. 
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In a study by Jain et al20, 55 women were studied to compare the 
efficacies of PGE1 and PGE2 in inducing second trimester abortion. 
Misoprostol was administered at a dose of 200 mcg every 12 hourly 
while 20 mg PGE2 was administered every three hours and concluded 
that misoprostol is as effective as PGE2 for the termination of second 
trimester pregnancy but it is less costly, easier to administer and is 
associated with fewer side effects. 
In a study by Bluementhal et al21, misoprostol application was 
compared with PGE2 and it was concluded that misoprostol was 
effective in achieving mid trimester abortion, had comparable induction 
abortion interval, low incidence of side effects and cost savings over 
PGE2. 
Nuutila et al22 compared two doses of intravaginal misoprostol 
and gemeprost for induction of second trimester abortion. Eighty one 
patients were recruited and were randomized to receive either 100 mcg 
every 6 hours, 200 mcg every 12 hours or gemeprost every 3 hours. I – 
A interval were respectively 23.1 hrs 27.8 hrs and 14.5 hrs.  
Ho et a123 studied the effect of vaginal vs oral misoprostol in 
terminating second trimester pregnancy after pretreatment with 
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mifepristone. Thirty six hours after 200 mg of oral mifepristone, women 
were given oral or vaginal misoprostol 200 mcg every three hours for a 
maximum of five doses. I-A interval, misoprostol required were reduced 
and success rate increased in vaginal group and maximum dose of 
Misoprostol used in vaginal group was 600mcg and in oral group was 
1000mcg.  
Eng et a124 compared the efficacy of vaginal misoprostol and 
gemeprost in inducing second trimester abortion. Fifty patients 
participated in the study and the misoprostol group received 200 mcg 
every three hours upto a maximum dose of 1200 mcg. Gemeprost group 
received 1 mg of the same three hourly upto a maximum dose of 5 mg. 
They found that majority of patients in misoprostol group aborted 
between 7 to 12 hours whereas majority of patients in gemeprost group 
aborted in the first six hours after induction.  
They concluded that intravaginal misoprostol was at least as 
effective as gemeprost as an abortifacient in second trimester pregnancy 
with intrauterine death but it was less costly, did not require 
refrigeration and was associated with lesser side effects.  
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In a study by Akoury et a125, the efficacy, outcome and 
acceptability of oral misoprostol, vaginal misoprostol and intra amniotic 
PGF2α. (IAPG) were compared in second trimester abortion. Their 
results were that the oral misoprostol group had significantly longer 
delivery time (29 hours) than vaginal misoprostol group (16 hours) and 
IAPG (18 hours). Women in the vaginal misoprostol group were most 
satisfied with the procedure and had fewer side effects than the other 
two groups. Failure rates for umbilical cord cultures were maximum for 
IAPG. 
Dickinson et al26 conducted a prospective randomized, 
double-blind, controlled clinical trial in 100 women between 14 and 28 
weeks gestation using either: 
- 1 mg gemeprost 3 hourly for 5 doses or 
- 200 mcg vaginal misoprostol 6 hourly for 4 doses. 
Delivery within 24 hours occurred in 75.1 % of women receiving 
gemeprost and 74.9% receiving misoprostol (NS). They concluded that 
intravaginal misoprostol performs as effectively as gemeprost in 
achieving delivery in the second trimester without an increase in adverse 
effects and displaying a significant cost advantage. 
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In a study by Biswas et al27 in group 1, 600 mcg misoprostol was 
given vaginally followed by 400 mcg 8 hourly upto a maximum of 48 
hours. In group 2, 150 ml of ethacridine was instilled extra amniotically. 
 They found that mean induction abortion interval in group 1 was 
13.94 hrs and in group 2 it was 28.86 hrs (p< 0.0001). Complications 
were noted in 32% women in group I and 44% in group 2.  
 Vaginal administration of misoprostol appears to be effective and 
well tolerated with less side effects and no complications and was 
cheaper. 
The evidence based regimen of the Royal College of Obstetrics 
and Gynecology{RCOG}is 400 mcg of Vaginal misoprostal every 3 
hours up to 5 doses in pregnancy between 13-22 weeks28. 
Prior uterine scar / Prior Cesarean 
 Increasing rates of cesarean delivery mean that more women with 
a histoy of uterine scarring will confront second trimester induction. 
Although the absolute risk or uterine rupture during second-trimester 
induction is unknown, most studies suggest that misoprostol can safely 
be used in postcesarean pregnancies.30,31,32 
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 Case reports describe uterine rupture among women with and 
without prior uterine scars undergoing PG induction throughout a wide 
range of gestational ages33 between 15 and 35 weeks,  prior cesarean 
section did not increase the risk of hemorrahage (2% vs 0.9%; P=.56) or 
the median induction-abortion interval (8.5 vs 9.0 hours; P=.26). 1 case 
of uterine dehiscene were noted, both in women with prior cesarean 
section and women without uterine scar. Conversely, a series reported 
by Daskalakis et al34 of 108 women with prior cesarean undergoing 
seond-trimester misoprostol induction reported only 1 case of uterine 
rupture but it occurred in 1 of the 216 nonscarred control subjects. 
Because rates of rupture may increase with advaning gestational age 
some author’s have advocated avoiding its use in the third trimester.35  
VARIOUS STUDIES OF MIFEPRISTONE 
Dosage of Administration 
In a randomized study by Webster D, Penney GC, Templeton 
A9, The intervention is administration of either 600mg or 200mg 
mifepristone 36 to 48 hours prior to prostaglandin. 
The geometric mean induction abortion interval was 6.9h and 
6.9h in the 600mg and 200mg groups, respectively (no significant 
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difference). The median dose of misoprostol was 1600 micrograms in 
each group.  
As with first-trimester abortion, randomized studies consistently 
indicated 200 mg of mifepristone is equally effective as 600 mg for 
termination of pregnancy in the second trimester.9,10   
INTERVAL BETWEEN MIFEPRISTONE AND MISOPROSTOL 
When the interval between mifepristone and misoprostol 
adminsitration was reduced to 24 hours, the induction-to-abortion 
interval was somewhat longer than after a 48-hour interval. In a 
retrospective study, time to fetal expulsion was 9.8 hours in the 24-hour 
interval group compared with 7.5 hours when the interval was 48 hours 
(P<.01), and in a randomized study it was 7.3 vs 6.2 hours (P < 05), 
respectively. 36-37 This latter study also reported a higher rate of uterine 
curettage with the 24-hour interval (P<.001). 
In this study by D.R. Urquhart and A.A. Templeton38, 
mifepristone (600 mg) was administered 24, 36 and 48 h prior to extra-
amniotic infusion of prostaglandin. No bleeding was observed prior to 
prostaglandin infusion in any of the groups and it is suggested that 
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mifepristone could be administered safely prior to hospital admission for 
termination.  
Mifepristone with misoprostol studies:  
In this randomized study by Suk Wai Ngai,Oi Shan Tang and  
Pak Chung Ho39  ,the hypothesis that oral misoprostol 400 μg is as 
effective as vaginal misoprostol 200 μg when given every 3 h in 
termination of second trimester pregnancy after priming with 
mifepristone was tested.  
 For the oral group, both the incidence of diarrhoea (40%  versus 
23.2%, P = 0.03) and the amount of drug used (1734 compared with 
812 μg, P < 0.0001) were significantly higher than that of the vaginal 
group but the incidence of fever appeared to be lower (not significant). 
   There was no significant difference in complete abortion rate: 
81.4% in the oral group and 75.4% in the vaginal group. The median 
induction–abortion interval was similar in the two groups (10.4 versus 
10.0 h). Overall, 82.0% of women preferred the oral route. Oral 
misoprostol (400 μg) given every 3 h up to five doses, when combined 
with mifepristone, was as effective as the vaginal (200 μg) route in 
second trimester termination of pregnancy. This regimen could also be 
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offered to those women who found repeated vaginal administration 
unacceptable. There are several advantages in using the oral route like 
(i) It is more convenient to administer; (ii) It is preferred by the majority 
of women & (iii) Misoprostol is manufactured for administration by the 
oral route.  
 In the study by El-Refaey et al 40(1995), women were pretreated 
with 600 mg oral mifepristone. After 36–48 h, they were randomized to 
group 1: vaginal misoprostol 600 μg followed by vaginal misoprostol 
400 μg given at a 3 h interval; group 2: vaginal misoprostol 600 μg 
followed by oral misoprostol 400 μg doses given at a 3 h intervalof four 
doses. They achieved an overall successful abortion rate of 97% and a 
mean induction to abortion time of 6.4 h (95% confidence interval 5.6–
7.0 h).  
 Ashok et al.41 (1999) reviewed 500 women who underwent 
second trimester termination of pregnancy. Women were given a single 
oral dose of mifepristone 200 mg and 36–48 h later, vaginal misoprostol 
800 μg. Three hours following the first dose of misoprostol, 400 μg 
doses were administered orally at 3 h intervals, to a maximum of four 
doses, and 97% aborted successfully. The median induction-to-abortion 
interval after the first prostaglandin administration was 6.5 h. It seems 
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that the first dose of misoprostol, when it is given vaginally at high dose, 
is important in reducing the induction–abortion interval. 
In a study by Haitham Hamodal, Premila W. Ashok, Gillian  
.M. Flett and Allan Templeton42 Mifepristone (200 mg) was followed 
36–48 h later by sublingual administration of oral misoprostol 600 μg or 
vaginal misoprostol 800 μg. This was followed by 3 hourly doses of 
misoprostol 400 μg administered sublingually or vaginally.  
Sublingual administration of misoprostol following mifepristone 
is an acceptable and effective alternative to vaginal administration for 
medical abortion at 13–20 weeks gestation.  
A retrospective audit by Rose SB, Shand C, Simmons A43shows 
prospectively collected notes for 272 women presenting for mid-
trimester termination of pregnancy by Mifepristone with vaginal 
misoprostol.  
The median time to abortion was 6 hrs, and mean number of 
doses of misoprostol was three. The proportion of women who aborted 
within 24 hrs was 95.9%. Immediate surgical evacuation of retained 
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placenta was required in 22 women (8.1%). Heavy bleeding occurred in 
22 women (8.1%), and seven required a transfusion (2.6%). The 
proportion of women who required parenteral narcotics was 78.2%. 
Our experience supports the finding that the use of mifepristone 
as pretreatment to misoprostol results in a shorter induction-to-delivery 
interval than the use of misoprostol alone as has been reported by other 
groups. 
A retrospective analysis  was carried out by Sin Ee Goh, Kok 
Joo Thong44 of 386 women who underwent termination of pregnancy 
between 12 and 24 weeks gestation.Each woman received 200 mg 
mifepristone orally followed by vaginal misoprostol 800 μg 36 to 48 h 
later. Three hours after the initial misoprostol administration, 400mcg 
doses of vaginal misoprostol were administered every 3 h, to a 
maximum of four doses in 24 h. If abortion failed, 200 mg mifepristone 
is given again 3 h after the last misoprostol dose, followed by 12 h of 
rest before vaginal misoprostol administration is repeated as per 
previous course of treatment. 
Overall, 97.9% and 99.5% of the women aborted within 24 and 
36 h, respectively. The median induction-to-abortion interval was 6.7 h 
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(range: 1.4–73.8 h), and nulliparous women took significantly longer 
time to abort (6.0 h in multiparous women compared to 7.6 h in 
nulliparous women; p<.0001). One woman failed to abort within 48 h. 
Surgical evacuation of the uterus was performed in 5% of women for 
incomplete abortion or retained placenta. Multiparous women were less 
likely to need analgesic administration for pain relief, and to experience 
vomiting and diarrhea, than nulliparous women. 
 Kapp N, Borgatta L, Stubblefield P, Vragovic O, Moreno N.45 
did a randomized, placebo-controlled, double-blind trial of mifepristone 
in second-trimester induction termination using misoprostol after 
feticidal digoxin. Women seeking abortion between 18 and 23 weeks of 
gestation were offered enrollment.  
Of 64 women, 32 received mifepristone and 32 received placebo. 
Median procedure time was significantly shorter for those who received 
mifepristone, 10 hours (95% confidence interval [CI] 8-12), than those 
who did not, 18 hours (95% CI 15-22), P<.01, and those parous, 10 
hours (95% CI 9-14), compared with nulliparous, 16 hours (95% CI 12-
22, P=.02). Other findings in the mifepristone compared with placebo 
group included rates of placental retention, 3.1% compared with 6.3% 
(P=.61), length of hospitalization, 0.66 days compared with 0.8 days 
37 
 
(P=.23), and analgesic requirements, 27.2 mg compared with 39.3 mg 
morphine (P=.22). Side effects during induction were similar between 
groups. 
Addition of mifepristone in second-trimester termination 
inductions using misoprostol significantly reduces the abortion time 
interval. 
DICKINSON, J. E., BROWNELL, P., McGINNIS, K. and 
NATHAN, E. A. 46 (2010), did a study in 388 women with prenatally 
recognised fetal anomalies between 14 and 24 weeks gestation 
underwent medical termination: 189 with misoprostol alone and 199 
with mifepristone priming followed by misoprostol. The median 
abortion duration was 15.5h  in the misoprostol group and 8.6 h in the 
mifepristone primed group (P < 0.001). In both the groups, nulliparity 
and advancing gestation were associated with a significant prolongation 
of the abortion interval.  
In a ongoing study by Gynuity health  projects47  ,Mifepristone 
Plus buccal Misoprostol Versus buccal Misoprostol Alone for 2nd 
Trimester Abortion (14 - 21 Weeks)were studied. This study is currently 
recruiting participants.  
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Mifepristone 200 mg orally Æ 36 hours later: Misoprostol 
800mcg vaginally Æ 3 hours later: Misoprostol 400mcg (buccal) every 
3 hours until delivery or a maximum of 5 doses in 24 hours or 10 doses 
in 48 hours.  In the misoprostol alone group,the same protocol was used 
without Mifepristone. Placebo was used instead. 
In the study of Hammond recent advances in second trimester 
abortion48, the recommended regimen of Royal College of 
Obstetricians and Gynecologists was given below: 
Day One: Mifepristone 200 mg orally Æ 36-48 hours later: 
Misoprostol 800mcg vaginally Æ 3 hours later: Misoprostol 400mcg 
orally or vaginally every 3 hours until delivery or total of 4 doses. Æ If 
undelivered 3 hours after 4th dose: Repeat Mifepristone 200 mg and 
resume induction next day or consider surgical abortion. 
 In the study of Bartley and Baird49  200mg Mifepristone 36-48 
hrs prior administration of 800mcg misoprostol vaginally followed by 
400 mcg oral misoprostol every 3 hrs of 4 doses. I-A interval was 6.1 
hrs and success rate was 94% in 24 hrs.    
 In the study of Ngai et al,50 200mg  Mifepristone 36-48 hrs prior 
administration of 400mcg misoprostol orally at 3hrs interval of 5 doses 
and success rate was 81.4% in 24 hrs and induction abortion interval 
was 10.4hrs and mean misoprostol dose was 1200mcg.   
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AIMS AND OBJECTIVES 
 To compare the abortifacient efficacy of vaginal misoprostol 
with mifepristone and vaginal misoprostol alone in second 
trimester pregnancy termination. 
 To compare the induction -abortion intervals. 
 To compare side effects and complications. 
 To compare the Cost effectiveness. 
 To identify the suitable method for second trimester MTP by 
comparing the various  parameters. 
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MATERIALS AND METHODS 
 This study comparing the efficacy of mifepristone – vaginal 
misoprostol combination with vaginal misoprostol alone as a method of 
second trimester abortion conduct at Institute of obstetrics and 
Gynaecology, Chennai – 08 during October 2009 – October 2010.  
Study design: Prospective randomized comparative study.  
Study Place : Institute of obstetrics and Gynaecology, Chennai-8.  
Collaborating Unit : Department of family welfare, IOG.  
Study Population :  Patients requesting abortion in their second trimester 
at Department of family welfare, IOG and patients 
requiring abortion at second trimester at IOG, 
Egmore.  
Period of Study : OCT2009 – OCT2010.       
Sample Size: 100 (Randam allocation to either group), 
50 – mifepristone + vaginal misoprostol group, 
50 – vaginal misoprostol group  
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Inclusion Criteria:  
 14 – 20 weeks gestation, Woman full filling the MTP indicators 
as per the MTP act ,Single live fetus, Present with closed cervical 
os, No vaginal bleeding and Patients consenting to this procedure 
only.  
Exclusion Criteria :  
 History of previous uterine surgery (but not a contraindication), 
Known allergy / Contraindications to mifepristone (or misoprostol 
/ prostaglandin), Multiple fetus, Intra uterine fetal demise, 
Presentation in active labour, Low lying placenta.  
METHODOLOGY: 
Mifepristone – misoprostol group:  
Dosage schedule:  
Day I: 200mg mifepristone was given orally and pt observed in 
ward itself,  after 36 hrs Pt shifted to labour ward and misoprotol 
800mcg administered vaginally          3 hrs Later  Misoprostol 400 mcg 
vaginally every 3 hrs  Until delivery (or total of 4 doses). If undelivered 
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3 hrs after 4th dose repeat mifepristone 200mg and resume induction 
next day or consider surgical abortion 
Misoprostol group:  
 Patient was asked to empty the bladder and was asked to lie down 
in the dorsal position with knee semiflexed and hip abducted.  
 800mcg misoprostol moistoned with saline inserted in posterior 
vaginal fornix , 3hrs later misoprostol 400mcg vaginally every 3hrs until 
delivery or total of 4 doses.  
 Additional measures were adopted in patients with incomplete 
abortion like instrumental evacuation, oxytocin infusion.  
 In patients who failed to expel at the end of 48hrs further 
management was determined by the unit policy.  
 Check USG done next day after expulsion to exclude retained 
products. If determined products present further management done .  
OUTCOME  
COMPLETE: When both placenta and fetus were expelled in 48 
hours.  
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INCOMPLETE: When either placenta or fetus was retained. 
FAILED: Neither fetus nor placenta was expelled. 
PARAMETERS STUDIED: 
1. Induction - Abortion Interval ,Complete abortion rate, Success rate , 
Side Effect Profile 
Vomiting , Diarrhoea, Fever, Headache, Rigor, Hemorrhage, 
Infection 
3. Total Number of Misoprostol Doses Required 
4.  Need For Additional Procedures Like Curettage , Misoprostol or 
Oxytocin 
5.  Requirement Of Transfusion 
6.   Cost in both groups  
Data was analyzed using SPSS software using ANOVA, 
Independent sample test and Chi-Square test and significant p-value 
being less than 0.05. 
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OBSERVATIONS 
PATIENT CHARACTERISTICS: AGE DISTRIBUTION 
TABLE 1: AGE DISTRIBUTION 
Age Group 
{Years} 
Mife+Miso 
n=50 
miso only
n=50 total 
N % N % N % 
<20 9 18.0% 6 12.0% 15 15.0% 
21-25 19 38.0% 21 42.0% 40 40.0% 
26-30 18 36.0% 17 34.0% 35 35.0% 
> 30 4 8.0% 6 12.0% 10 10.0% 
Total 50 100% 50 100.0% 100 100.0% 
Mean Age in 
years 
24.9400 25.1000  
SD 4.03763 4.22939  
  
Age distribution was similar in both groups . Majority of patients 
in either group were in the age group of 21-25 years. 
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GRAVIDA 
TABLE 2: GRAVIDA 
Gravida 
Mife+miso 
N=50 
Miso only 
N=50 Total 
N % N % N % 
1 15 30% 10 20% 25 25% 
2 12 24% 17 34% 29 29% 
3 18 36% 19 38% 37 37% 
4 3 6% 4 8% 7 7% 
5 2 4% 0 0% 2 2% 
Total 50 100% 50 100.0% 100 100.0% 
 
Forty Six Percent of patients in both group was gravida Three and 
above. 
 
30
24
36
6
4
20
34
38
8
0
0
5
10
15
20
25
30
35
40
1 2 3 4 5
PE
R
C
EN
TA
G
E
GRAVIDA
GRAVIDA DISTRIBUTION
MIFE+MISO
MISO
46 
 
GESTATIONAL AGE AT TIME OF TERMINATION 
TABLE 3: GESTATIONAL  AGE GROUP  
GA {weeks} 
Mife+miso 
N=50 
Miso only 
N=50 Total 
N % N % N % 
14-16 week 6 12% 3 6% 9 9% 
17 -18 week 27 54% 28 56% 55 55% 
19-20 week 17 34 19 38% 36% 36% 
Total 50 100% 50 100% 100 100% 
Mean  18.08 18.44  
pvalue 0.159   
 
Most of the pregnancies were terminated in 17 to 18 weeks of 
gestation in both groups  
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INDICATIONS FOR TERMINATION 
TABLE 4: INDICATIONS FOR TERMINATION 
Indication 
Mife+miso 
n=50 
Miso only 
n=50 
Total 
n % n % n % 
ANOMALOUS 6 12.00% 3 6.00% 9 9.00% 
UNWANTED 33 66.00% 33 66.00% 66 66.00% 
UNWED 11 22.00% 14 28.00% 25 25.00% 
Total 50 100.00% 50 100.00% 100 100.00%
 
Social reasons account for most of the reasons for MTP. 
Unwanted Pregnancies accounts for Sixty Six  percent in both groups.  
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PARAMETERS STUDIED 
INDUCTION-ABORTION INTERVAL 
TABLE 5: INDUCTION-ABORTION INTERVAL 
Induction 
Abortion 
Mife+Miso 
n=50 
Miso only 
n=50 
P value 
Mean 8.2290 12.8583  P=0.000  <  
0.001   
SIGNIFICANT.  
Std. Deviation 3.29394 3.67504  
Std. Error Mean .46583 .53045 
 
Mean Induction-Abortion (I-A) interval in mife+miso group was 
8.2 hrs and in miso  group was 12.8 hrs. The difference between them 
was found to be statistically significant (p value 0.000). 
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INDUCTION – ABORTION INTERVAL 
TABLE 6: INDUCTION-ABORTION INTERVAL& PARITY 
Parity Mife+ Miso group 
Hrs 
Miso group 
Hrs 
G1  11 14.4 
G2 9.8 13.4 
G3 6.5 12.2 
G4 & Above 5.2 9.1 
P Value  0.01 0.54 
 
I-A Interval is shortened in Multigravida Compared to 
Primigravida in both groups. In Mife+miso group it is statistically 
significant (P Value 0.01) 
 
 
0
2
4
6
8
10
12
14
16
G1  G2 G3 G4 & 
Above
I‐
A
 IN
T 
(H
O
U
RS
)
Parity
PARITY
Mife+ Miso group
Miso group
  
Gestati
14-1
17-1
19-2
P V
Accord
0
2
4
6
8
10
12
14
I‐A
  I
N
T 
(H
O
U
RS
)
INDUCT
TABLE 
GESTAT
onal Age 
6wks 
8wks 
0wks 
alue 
ing to GA
GE
ION – A
7: INDUC
IONAL A
Mife+
0
, I-A Inter
14‐16wks
WEEK
STATION
 
BORTION
TION-AB
GE 
miso grou
Hrs 
11.1 
7.9 
8 
.124 
val is not 
17‐18wks
S
AL AGE
 INTERV
ORTION
p M
statisticall
19‐20wks
 & I‐A IN
AL 
 INTERV
iso group
Hrs 
12.2 
12.5 
13.7 
0.978 
y significa
T
M
M
50
AL & 
 
nt 
ife+miso group
iso group
 
DO
 
d
in 
 
SES REQ
M
Total  
osage 
 
Mean do
the miso  g
M
IS
O
PR
O
ST
O
L 
D
O
SA
G
E
UIRED 
TA
ethod gr
Mife+mi
Miso on
se require
roup was 
0
500
1000
1500
2000
D
BLE 8: D
oup N
so 5
ly 5
d in mife+
1992 mcg
 
Mife+miso
M
OSAGE
OSES RE
 Me
0 1376.
0 1992.
miso grou
.  
Miso 
ODE
 COMPA
QUIRED
an SDev
0000 512.
0000 438.
p was 137
only
RISON
 
td. 
iation 
St
12243 72
84821 62
6 mcg wh
M
51
d. Error 
mean 
.42505 
.06251 
ile that 
 
ean
52 
 
Repeat Dosage 
TABLE 9:Repeat Dose of Misoprostol Required for Abortion 
Mode 
Number of doses 
0 1 2 3 4 
Mife+Miso 15 14 8 10 3 
Miso 0 7 9 12 22 
 
The Repeat dose required in mife+miso group was lesser while that 
in the miso  group was comparatively more.  
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TABLE 10: OUTCOME IN BOTH GROUPS 
 
Mife+Miso Group Miso Group 
p - Value 
N % N % 
Complete 45 90 36 72 0.53 (NS) 
Incomplete 5 10 12 24  
Failure 0 0 2 4  
 
 
 
The percentage of complete abortion in Mife + Miso  group was 
90% while that in Miso group was 72%.The difference between the two 
group was not statistically significant. The percentage of incomplete 
abortion was 10% in Mife + Miso group and 24% in Miso group which 
was not statistically significant. There is no failure in Mife + Miso group 
and 4% in miso group which was not significant statistically. 
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TABLE 11: SUCCESS RATES IN BOTH GROUPS 
Hours Mife+miso group Miso group 
0-<12 hours 38 18 
12-24 hours 12 30 
25-36 hours - - 
37-48 hours - - 
Failure  2 
 
Successful abortions included those patients who expelled 
completely or incompletely within forty eight hours. The number of 
successful abortions in Mife + Miso group was 100% and that in miso 
group was 96%. 
Seventy Six percent of patients in Mife + Miso group expelled 
within twelve hours as apposed to Thirty Six percent in Miso group. 
With Mife + Miso group, 100% of the women had expelled in 24 hours 
while with Miso group, 94% had expelled in the same time.
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ADDITIONAL INTERVENTIONS 
TABLE 12: ADDITIONAL INTERVENTIONS 
Intervention Mife + Miso Miso P Value  
Instrumental Evacuation 3 9  
 
0.154 
(NS) 
Misoprostol - 2 
Oxytocin 2 1 
Mife + miso - 2 
Total 10% 28% 
 
 Overall 10%  in mife + miso group and 28% patients in miso 
group required some form of interventions for completion of the  
abortion process. The commonest intervention in both group was 
instrumental evacuation.  
Additional procedures like CUT insertion and tubectomy done in  
multigravida.   There was no incidence of postprocedural infections or 
sepsis in either group. 
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ANALYSIS OF SYMPTOMS 
TABLE 13: ANALYSIS OF SYMPTOMS 
S.No Symptoms 
Mife+miso 
group Miso group P Value 
N % N % 
1. Nausea  11 22 17 34 0.181 
2. Vomiting 7 14 13 26 0.1337 
3. Rigor 6 12 11 22 0.183 
4. Pain 10 20 19 38 0.473 
5. Fever 5 10 8 16 0.371 
6. Excessive 
bleeding PV 
2 4 3 6 0.650 
7. Diarrhoea 1 2 2 4 0.557 
 
There was no statistically significant side effects between two 
groups.  Side effects were treated symptomatically and no major 
complications were found in both groups. 
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TABLE 14: COST INCURRED IN BOTH GROUPS 
 Method 
group 
Min 
cost per 
dose 
Avg. 
cost Mean 
Std. 
Deviatio
n 
Std. 
Error 
mean 
Cost  
Rupees 
Mife+miso 427 483.16 483.1
600 
49.9319
4 
7.061
44 
Miso only 117 194.22 194.2
200 
42.7877
0 
6.051
09 
 
In this study, the minimum cost per dose of Mife + Miso group 
was Rs.427 while that of misoprostol group was Rs.117.  
The average cost in this study in  Mife + Miso group was 
Rs.483.16 and Rs.194.22 in miso group 
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DISCUSSION 
The various methods used for second trimester termination of 
pregnancy are undergoing critical appraisal worldwide. Misoprostol, 
although being used routinely for second trimester MTP has the 
disadvantages of long induction-abortion interval, more chances of 
incomplete abortion and high failure rate. Recently, Mifepristone and 
Misoprostol combination has been found to be very effective in the 
termination of second trimester pregnancy with short induction-abortion 
interval and high success rate inspite of its high cost. The present study 
evaluated the time-trusted method of instilling Vaginal Misoprostol with 
Mifepristone versus vaginal administration of Misoprostol alone in 
second trimester pregnancy termination. 
The present study done at Institute of Obstetrics and 
Gynaecology, Egmore, was a randomized comparative study of 100 
patients with gestational age between 14-20wks admitted for unwanted 
pregnancy or anomalous fetus. Group I (50 patients) received 200 mg of 
Mifepristone and 800 mcg vaginal misoprostol  after 36 hours, followed 
by 400 mcg vaginal misoprostol every three hours (maximum of four 
doses) or until delivery and Group II (50 patients) received 800 mcg 
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vaginal misoprostol  followed by 400 mcg vaginal misoprostol every 
three hours (maximum of four doses) or until delivery for induction of 
abortion. 
Patient Characteristics  
Age:  
 In this study, the mean age of patients in mifepristone + 
misoprostol group was 24.9years with a range of 16-35 years and the 
mean age of patients in misoprostol group was 25.1years with a range of 
18-36 years. There was no association between advancing maternal age 
and induction abortion rates or complete abortion rates in our study. 
 This was comparable to the study of KAPP, NATHALIE MD, 
MPH45  the mean age of mifepristone + misoprostol was 25.7 years and 
that in misotropol was 25.5years.  
 In the study of JAN E DICKINSON46 the mean age of 
mifepristone + misoprostol was 32 years and that of misoprostol was 32 
years.   
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Gravida:  
 In the present study at least one prior delivery accounted for 24% 
in the mifepristone + misoprostol group and 34% in the misoprostol 
group.  
 In the study of JAN E DICKINSON46  mifepristone + misoprostol 
group was 57.8% and misorpostol group was 60.3%. 
Gestational age:  
 In the present study, the mean gestational age in mifepristone + 
misoprostol group was 18.08 weeks while that in misoprostol group was 
18.44 weeks.  
 In the study of JAN E DICKINSON46  the mean gestational age 
was 19.1 weeks in mifepristone + misoprostol group and 19.6 weeks in 
misoprostol group.  
Indication:  
 In this study, the most common indication for pregnancy 
termination was unwanted pregnancy and  it accounts for 66% in both 
groups and it is comparable with other studies.   
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Parameters Studied :  
Induction abortion:  
In the present study the mean induction abortion interval was 8.2 
hrs for mifepristone + misoprostol group and 12.8hrs for misoprostol 
group which was statistically significant (<0.000)  
In the study of JAN E DICKINSON46 the mean induction 
abortion interval was 8.6hrs for mifepristone + misoprostol group and 
15.5hrs for misoprostol group.  
  TABLE 15: I-A INTERVAL AND SUCCESS RATES IN 
VARIOUS STUDIES 
Study 
Induction – Abortion 
interval (hours) Success rate (%) 
Mifepristone 
+  
Misoprostol 
Misoprostol 
Mifepristone 
+ 
misoprostol 
Misoprostol 
JAN E 
DICKINSON 
46 
8.6 15.5 98% 96.3% 
KAPP 
NATHALIE45 
MD, MPH  
10 18 99% 97% 
PRESENT 
STUDY 2010 8.2 12.8 100% 96% 
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It is known that induction of labour is easiliy accomplished in 
multiparous compared with primiparous51,52 women, in our study also 
the induction abortion interval is shortend in multiparous compared to 
primiparous woman in mife + miso group. 
TABLE 16: I-A INTERVAL IN PARITY 
Study 
Nulli parous Multiparous 
Mifepristone 
+ Misoprotol 
(hrs) 
Miso 
prostol 
(hrs) 
Mifepristone 
+ Misoprotol 
(hrs) 
Misoprostol 
(hrs) 
JAN E 
DICKINSON46  
11 16.8 6.9 14.1 
PRESENT 
STUDY 2010 
11 14.4 7.4 11.6 
   
In the study of JAN E DICKINSON46  with increasing gestational 
age the induction abortion interval was prolonged. In our study with 
increasing gestational age the induction abortion interval was prolonged 
in Misoprostol group but it was not statistically significant. 
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TABLE 17: I-A INTERVAL IN VARIOUS STUDIES 
 
STUDY 
Dose(mcg) 
Dosage 
Interval  (hours) 
I-A Int 
(hours) 
Jain et al14 200 12 12 
Bebbington et al 11 600 - 400 4 19.6 
Jain et al14 200 6 13.8 
Herabutya et al15 600 12 15.2 
Herabutya. et al15 800 12 15.3 
Bluementhal et al21 200 3 9.5 
Nuutila et aI22 100 6 23.1 
Nuutila et aI22 200 12 27.8 
Tang et al12 400 3 10.5 
Dickinson 26 400 6 15.1 
Present study 2010 800-400 3 12.8 
Table 2 : Mean dosage of Drug required (Misoprostol)  
Mean dose of drug required  
In our study, the mean dose of misoprostol required in 
pretreatment with mifepristone was 1376 mcg while in misoprostol 
group was 1992 mcg . In the study of JAN E DICKINSON46  the dose 
required in both groups were 1600mcg.  
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TABLE 18:DOSAGE OF MISOPROSTOL  IN MISOPROSTOL 
ALONE GROUP 
Study Misoprostol Mean 
(mcg) dose 
Induction – 
Abortion Interval 
Snehamy  
Chaudhri et al18  
760 15.5 
C.S,W,Ngai et al23  2000 16.3 
Jan E Dickinson46 1600 15.5 
Present Study 2010 1992 12.8 
  
TABLE 19: DOSE OF VAGINAL MISOPROSTOL  
USED IN VARIOUS STUDIES IN  
MIFEPRISTONE + MISOPROSTOL GROUP 
S. 
No Study 
Mife 
pristone 
Dose (mg) 
Inerval 
between 
mife 
pristone – 
misoprosto
l (hrs) 
Misoprostol 
(Mean dose) 
(Mcg) 
Induction
- Abortion 
Interval 
(hrs) 
1 WEBSTER D9 200 mg – 
600 mg 
36-48 1600 6.9 
2 SUKWAI NGAI OI 
SHAN TANG AND 
PAK CHANG39  
200 mg  36-48 812 10 
3 ROSE SB, SHANG C, 
SIMMONS A43  
200 mg  36-48 1200 6 
4 JAN E DICKINSON46  200 mg  36-48 1600 8.6 
5 HAMODA ET – AL42 200 mg  36-48 1600 5.4 
6 E1 – REFAEY AND 
TEMPLETON40  
600 mg  36-48 2200mcg 
over 12 hr 
well towarted  
6.4 
7 ASHOK AND 
TEMPLETON41 (1999) 
200 mg  36-48 1200 mcg  6.5 
8 HAMMOND (RCOG)48 200 mg  36-48 1200 mcg  7.4 
9 PRESENT STUDY  200 mg  36 hrs  1376 mcg 8.2  
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Studies have shown that pretreatment with mifepristone results in 
shorter induction – abortion intervals compared to misoprostol group 
alone and also dose of misoprostol required is reduced.  In the study of 
El. Refaey and Templeton40 2200mcg over 12 hrs and 4000mg over 48 
hrs were well tolerated.  
OUTCOME: 
  The success rate at less than  12 hrs was 76% with in mifepristone 
+ misoprostol group and 36% with in misoprostol group which is greater 
than most of the observations in other studies probably because of the 
high dose and shorter dosing interval41. But the final success rate at 
24hrs and 48 hrs in the present study was 100% with mifepristone + 
misoprostol group and 96% in misoprostol group which is comparable 
to other studies. 
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TABLE 20 : OUTCOME IN VARIOUS STUDIES 
(MISOPROSTOL) 
Study 
Success rates of misoprostol-n(%) Failure - 
N (%) and 
 mode of 
Termination 
12 hrs 24hrs 36 hrs 48 hrs 
CHAUDURI 
ET AL18 
21 
(35%) 
45 
(75%) 
53 
(88%) 
(57) 
95% 
3(5%) - 2 
received PGF2α 1 
hysterotomy was 
done 
BISWAS ET 
AL27 
(5) 
20% 
21 
(84%.) 
23 
(92%) 
- 2(8%) Not 
mentioned 
YAPAR ET 
AL19 
- - - 38 
(77.5%) 
11(22.5%) 
TANG ET 
AL12 
 96 
(86%) 
 106 
(95%) 
6(5%) 1 expelled 
spontaneously 
remaining 5 
aborted with intra 
vaginal gemeprost 
JAIN ET 
AL20 
- 81 
(81%) 
100 
(100%) 
 - 
ENG ET 
AL24 
15(60
%) 
21 
(84%) 
- - 4 (16%) 1- 
sulprostone; 
remaining 3 
underwent 
suction 
evacuation 
PRESENT 
STUDY 2010 
36% 94% - 94% Mifepristone + 
misoprostol 
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TABLE 20 : OUTCOME IN VARIOUS STUDIES 
(MIFEPRISTONE WITH MISOPROSTOL) 
 
Study SUCCESS RATES OF MIFEPRISTONE + 
MISOPROSTOL IN VARIOUS STUDIES 
 12 hrs 24 hrs 36 hrs 48 hrs 
Sukwai Ngai  
Shan Tang and 
Pak Chang39 
 
Elrefaey et al40  
 
Ashok et al41 
 
ROSE SB Shand 
c43 
 
SIN Ee GOh, 
KokJoo Thong44  
 
JAN E 
DICKINSON46 
 
Present study  
2010 
70.4% 
 
 
 
 
 
 
 
 
 
 
 
 
 
70.4% 
81.4% 
 
 
 
97% 
 
97.1% 
 
95.9% 
 
 
97.9% 
 
 
91.5% 
 
 
100% 
 
99.5% 
 
 
 
98.3% 
 
 
 
 
 
 
99.5% 
 
 
98% 
97% 
 
 
 
99% 
 
99.2% 
 
 
 
 
99.5% 
 
 
 
 
 
100% 
 
Additional Intervention:  
 Additional intervention needed more in misoprostol group 
compared to mife + miso group and most of the Patients required 
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surgical evacuation in both both group  which was comparable with 
other studies. 
TABLE 22: INTERVENTIONS USED FOR  
INCOMPLETE ABORTIONS 
Study  Mode  n% Intervention  
KAPP NATHAL 
IE, MD, MPH45 
Mifepristone + 
Misoprostol 
------------------- 
Misoprostol 
3.1% 
 
6.3% 
Surgical Evacuation 
JAN E 
DICKINSON46 
Mifepristone + 
Misoprostol 
------------------- 
Misoprostol 
24.5% 
 
25.6% 
Surgical Evacuation 
SIN, EE, GOH, 
KOK, JOO 
THONG 44 
Mifepristone + 
Misoprostol 
------------------- 
Misoprostol 
5% 
 
6.5% 
Surgical Evacuation 
PRESENT 
STUDY 2010 
Mifepristone + 
Misoprostol 
------------------- 
Misoprostol 
10% 
 
24% 
Surgical Evacuation  
oxytocin infusion  
 
Surgical Evacuation 
oxytocin infusion ,miso 
prostol53  
 
Side effects:  
 There was no major side effects like uterine rupture, infection, 
sepsis, hypersensitivity reactions or maternal deaths in either group. 
Two patients in mifepristone plus misoprostol group and three patients 
in misoprostol group had bleeding more than 300ml which in all cases 
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this was due to incomplete abortion which was controlled by surgical 
evacuation. However no transfusion were required in either group.  
In the study of Tang et al 12  and HO et al 23  where dosing interval 
was frequent the incidence of side effects were more,  but in the present 
study it is comparable with other studies.  
Other Complications:   In the present study there was no post 
procedural gential infections or cervical tears which was comparable to 
others studies also.  
TABLE 23: SIDE EFFECTS IN VARIOUS STUDIES n(%) 
Study Mode Nausea Vomiting Diarr hoea Fever 
Excess 
Bleeding Rigor 
Cx 
Tear 
Chauduri 
et al18 
PGE1 - 9(15%) - 8 (13.3%) - - - 
 
Biswas et 
al27 
PGE1 1(4%) - - - - 4 (16%) - 
Bebbington 
et al 11 PGE1 - - - 
12 
(24%) - - - 
Jain at al14 PGE1 - 11 (4%) 11(4%) 
30 
(11%) - - - 
Nuutila 
et al22 
PGE1 
100mcg - 
6  
(22%) 0 - - - - 
Nuutila et 
al22 
PGE1 
200mcg - 
3 
(11%) 2(8%) - - - - 
Tang et 
Al12 PGE1 
53 
(48%) - 
29  
(26%) 
66  
(59%) - 
72 
(64%) - 
Ho et al23 PGE1 20 (40.8%) 
14 
(28.6%) 
9  
(18.6%) - - - - 
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TABLE 24: SIDE EFECTS IN VARIOUS METHODS 
Study Mode Nausea Vomiting Diarrhoea Fever Excessive bleeding Rigor 
Sukwai Ngai o 
Shan Tang and 
PAK Chung39  
Mifepristone 
+ 
Misoprostol  
  40% oral 
23.2% 
vaginal   
   
Haitham 
Homoda42 
Mifepristone 
+ 
Misoprostol 
26% 25% 25% - - 28%  
ROSE SB 
Shang C 
Simmon A 43 
     8.1%   
Jan E 
Dickinson 46 
Mife + Miso  
Miso  
   43.7%  
51.3% 
  
Present Study 
201029 
Mifepristone 
+ 
Misoprostol 
Miso  
22%  
 
 
26%  
14% 
 
 
26%  
2% 
 
 
4%  
 12% 
 
 
22%  
 
 
Cost incurred: 
Average cost in misoprostol group was rupees 194.22 while in 
mifepristone + misoprostol group was rupees 483.16  So Misoprostol 
group is very economical as mentioned in various studies.    
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SUMMARY 
1. One hundred Patients opting for second trimester pregnancy 
termination or diagnosed to have anomalous fetus were 
considered for the study. Fifty patients received 200mg 
Mifepristone ,followed by 800mcg vaginal misoprostol 36 hours 
later, followed by 400mcg vaginal misoprostol every 3 hours 
interval of maximum 4 doses or until delivery. In another fifty 
women, 800mcg vaginal misoprostol followed by 400 mcg 
vaginal misoprostol every 3 hrs interval of maximum 4 doses  or 
until delivery.  
2. The two groups were comparable with respect to maternal age, 
parity and gestational age at the time of induction of abortion. 
Majority of patients in either group were in the age group  of 21-
25 years. The commonest gestational age in both group was 
between 17-18 weeks. 
3. There were more multigravida than primigravida in both the 
groups. Induction abortion interval in primigravida is more 
compared to multigravida in both group and it was statistically 
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significant in Mifepristone and misoprostol combination 
(pvalue.01). 
4. The most common indication for pregnancy termination in both 
group  was unwanted pregnancy due to social reasons. 
5. Induction abortion interval in Mifepristone and misporstol group 
was 8.2 hours and that in misoprostol alone group was 12.8 
hours.The difference between them was found to be statistically 
significant (p value 0.000). 
6. According to the gestational age, induction abortion interval was 
not statistically significant in both groups 
7. The percentage of complete abortion in Mifepristone and 
misoporostol group was 90% and in misoprostol group was 72% 
but the difference was not statistically significant. The percentage 
of incomplete abortion was 10% in Mifepristone and misoprostol 
group and  was 24% in misoprostol alone group which did not 
reach statistical significance 
8. There was no failure in Mifepristone and misoprostol group and 
4% in misoprostol alone group, but it was not statistically 
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significant. The complete abortion rate within 12 hours was 76% 
in Mifepristone and misoprostol group and 36% in misoprostol 
alone group and in 24 hrs it was 100% and 96% respectively. 
Additional intervention needed in Mifepristone and misoprostol 
combination group was 10% and in misoprostol alone group was 
28%and most common being instrumental evacuation. 
9. The mean dose of misoprostol used was 1376 mcg and that of 
misoprostol group was 1992 mcg. 
10. The average cost in misoprostol alone group was rupees 194.2 
and Mifepristone and Misoprostol combination group was rupees 
483.1, which is two times higher. 
11. There was no statistically significant side effects between two 
groups and no major maternal complications found in both group. 
12. It  was observed that no bleeding (or) abdominal pain (or)any 
adverse reactions were not reported after administration of 
Mifepristone prior to vaginal Misoprostol administration(36 
hrs).so  Mifepristone could be administered safely prior to 
hospital admission for termination.   
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CONCLUSION 
Comparing Mifepristone and Vaginal misoprostol combination 
with vaginal misoprostol alone for second trimester pregnancy 
termination, it was observed that  
 Mifepristone with vaginal misoprostol combination group 
is associated with shorter induction abortion interval and  
100% success rate. The  complete abortion rate , success 
rate and side effects were comparable in both group. 
 Vaginal misoprostol alone group also dosen’t have the 36 
hours  anxiety/unease from the time of mifepristone 
administration. 
 Vaginal misoprostol alone group is cost effective.  
 Hence vaginal misoprostol alone group can also be 
considered as an effective alternative for Mifepristone and 
vaginal misoprostol combination group. 
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ABBREVIATIONS 
 
ACTH - Adrenocorticotrophic Hormone 
COX - Cyclo-Oxygenase 
CX - Cervix 
EAE - Extra Amniotic Ethacridine Lactate 
GA - Gestational age 
HRS - Hours 
hCG - Human Chorionic Gonadotropin 
I-A Int - Induction Abortion Interval 
IAPG - Intra Amniotic Prostaglandin 
LT - Leukotriene 
mcg - Microgram 
mg - milligram 
MTP - Medical Termination of Pregnancy 
Mife+Miso - mifepristone+misoprostol 
Miso - Misoprostol 
NS - Not Significant 
PG - Prostaglandin 
PO - Per Oral 
PV - Per Vaginal 
S - Significant 
SD - Standard Deviation 
WK - Week 
PROFORMA 
 
S.NO:    AGE:            IPNO: 
NAME:                              DOA:   HEIGHT: 
ADDRESS:    DOD:   WEIGHT: 
 
OCCUPATION: 
SOCIOECONOMICAL CLASS: 
MENSTRUAL HISTORY: 
LMP:    REGULAR/IRREGULAR 
MARITAL HISTORY: 
  MARRIED SINCE 
  UNMARRIED 
OBSTETRIC FORMULA: G_____ P_____ L_____
 A_____ 
PERIOD  OF GESTATION: 
H/O PREVIOUS MTP DONE: 
1. HOW MANY WEEKS 
2. METHOD ADOPTED 
REASONS FOR MTP: 
o SOCIAL  CAUSE 
o FAILURE OF CONTRACEPTION 
o CONGENITAL ANOMALIES 
o UNWED PREGNANCY 
o MEDICAL REASONS 
PAST MEDICAL HISTORY: 
History of DIABETES/HYPERTENSION/PULMONARY 
TUBERCULOSIS/BRONCHIAL ASTHMA/EPILEPSY/HEART 
DISEASE/ENDOCRINE DISORDER .     
     
H/O PREVIOUS SURGERY:    IF ANY: 
ON  EXAMINATION: 
GENERAL EXAMINATION: 
ANAEMIA  : YES/NO 
FEBRILE  : YES/NO 
PEDAL EDEMA : YES/NO 
TEMP   WT 
PR    
BP   CVS 
RR   RS 
PER ABDOMEN EXAMINATION: 
SPECULUM EXAMINATION: 
PER VAGINAL EXAMINATION: 
INVESTIGATIONS: 
 URINE ALBUMIN 
      SUGAR 
HB% 
BLOOD GROUPING/RH TYPING 
HIV(WITH CONSENT) 
VDRL 
BLOOD SUGAR,UREA,ECG,USG. 
DATE/TIME OF ADMINISTRATION OF 
MIFEPRISTONE; 
DATE/TIME OF ADMINISTRATION OF VAGINAL 
MISOPROSTOL: 
NUMBER OF DOSES: 
DATE/TIME OF EXPULSION OF FOETUS: 
DATE/TIME OF EXPULSION OF PLACENTA: 
OUTCOME 
COMPLETE:  
INCOMPLETE:  
FAILED:  
 
IF INCOMPLETE ADDITIONAL METHODS USED FOR 
COMPLETING THE ABORTION: 
ADDITIONAL INTERVENTIONS IF NEEDED: 
INDUCTION-ABORTION INTERVAL IN HOURS: 
SIDE EFFECTS: 
NAUSEA  RIGOR  
VOMITING  FEVER  
DIARRHOEA  HAEMORRHAGE  
HEADACHE  PAIN  
 
ADDITIONAL PROCEDURES: CUT/TUBECTOMY 
 
S. NO NAME
AGE in 
Years InPatient No PARITY GA INDICATION METHOD
INITIAL DOSAGE
Intial dosage 800 
Mcg
REPEAT 
DOSAGE
400 Mcg
TOTAL 
DOSAGE
IND‐ABO 
INTERVAL
In Hours RESULT ADD INT Side Effects COST{RS} Addl Pro
FAILURE 
EXPULSION TIME
1 ANANDHI 19 2879 G1 17 Unwed MIFE+MISO 1 3 2000 12 Complete   544
2 CHRISTINA 20 12100 G1 16 Unwed MIFE+MISO 1 3 2000 12 Complete   Rigor,Fever                       544
3 AGNES 19 11386 G1 20 Unwed MIFE+MISO 1 3 2000 12.3 Complete   544
4 REVATHY 19 11502 G1 17 Unwed MIFE+MISO 1 1 1200 7 Complete   Nausea,Vomiting,Pain              466
5 SUBHA 20 8517 G1 17 Unwed MIFE+MISO 1 3 2000 13 Complete   Rigor,Fever                       544
6 YASODHA 16 8113 G1 17 Unwed MIFE+MISO 1 1 1200 6.4 Complete   466
7 PARAMESWARI 19 18239 G1 18 Unwed MIFE+MISO 1 1 1200 7 Complete   Nausea,Vomiting,Pain              466
8 CHELLAMAL 20 23849 G1 16 Unwed MIFE+MISO 1 4 2400 16.1 Incomplete IE Fever,Vomiting                    583
9 PUSPA 18 19988 G1 16 Unwed MIFE+MISO 1 4 2400 16 Incomplete IE Pain                              583
10 UMA 19 12609 G2A1 18 ANOMALOUS MISO ONLY 1 4 2400 23.3 Complete   Rigor,Vomiting                    234
11 ELLANA 18 10349 G1 16 Unwed MISO ONLY 1 3 2000 11 Complete   Fever                             195
12 USHA 18 10972 G1 19 Unwed MISO ONLY 1 3 2000 12 Complete   Rigor,Fever,                      195
13 NISHA 19 11009 G1 20 Unwed MISO ONLY 1 4 2400 16.3 Incomplete IE Rigor,Diarrhoea,Bleeding                234
14 BOMMUKUTTY 20 11505 G1 17 Unwed MISO ONLY 1 4 2400 14.4 Complete   Vomiting                          234
15 SEETA 20 23208 G1 20 Unwed MISO ONLY 1 3 2000 13 Complete   195
16 Nathiya 23 2195 G3P1L1A1 20 Unwanted MIFE+MISO 1 2 1600 10 Complete   505 CUT
17 AMUDHA  23 2910 G1  18 Unwed MIFE+MISO 1 2 1600 10 Complete   505
18 ANANDAVALLI 25 8292 G2P1L1 17 ANOMALOUS MIFE+MISO 1 3 2000 13 Complete   Vomiting,Diarrhoea                544 CUT
19 PRIYA 25 7564 G1 17 Unwed MIFE+MISO 1 4 2400 16.4 Incomplete IE Rigor,Fever,Bleeding 583
20 MANJULA 25 8180 G3P2L2 18 Unwanted MIFE+MISO 1 0 800 4.2 Complete   Nausea,Pain                       427 TAT
21 BHAVANI 22 18764 G2P1L1 18 Unwanted MIFE+MISO 1 1 1200 7 Complete   Vomiting                          466 CUT
22 NEETHUSINGH 23 18872 G1 19 Unwed MIFE+MISO 1 1 1200 7 Complete   466
23 DEVI 23 19294 G1 16 Unwed MIFE+MISO 1 3 2000 13 Incomplete IE Rigor,Fever                       544
24 CHITRA 23 22594 G1 16 Unwed MIFE+MISO 1 0 800 4 Complete   Fever                             427
25 ROJAVATHY 22 22271 G1 18 Unwed MIFE+MISO 1 3 2000 13 Complete   544
26 SATHYA 22 22278 G2P1L0 18 ANOMALOUS MIFE+MISO 1 1 1200 10 Complete   466
27 AMBIGA 24 13953 G2P1L1 17 Unwanted MIFE+MISO 1 2 1600 9.2 Complete   505 CUT
28 MAHESWARI 24 14000 G2P1L1 20 Unwanted MIFE+MISO 1 2 1600 10 Complete   505 CUT
29 NIRMALA 24 13949 G2P1L1 18 Unwanted MIFE+MISO 1 0 800 4 Complete   Nausea,Pain                       427 CUT
30 PARVATHY 24 14146 G3P2L2 17 Unwanted MIFE+MISO 1 0 800 4.3 Complete   427 TAT
31 SUDHA 24 17193 G2P1L1 17 Unwanted MIFE+MISO 1 2 1600 10 Complete   505 CUT
32 REKA 23 18018 G2P1L1 20 Unwanted MIFE+MISO 1 3 2000 11 Complete   544 CUT
33 SILAMBARASI 23 20394 G2P1L1 19 Unwanted MIFE+MISO 1 2 1600 10 Complete   505 CUT
34 PRIYADARSHNI 25 18130 G3P2L2 20 Unwanted MIFE+MISO 1 1 1200 7 Complete   466 TAT
35 VALARMATHY 22 4567 G1 20 Unwed MISO ONLY 1 4 2400 17.1 Incomplete IE 234
36 REVATHY 22 10784 G1 20 Unwed MISO ONLY 1 4 2400 14.3 Complete   234
S. NO NAME
AGE in 
Years InPatient No PARITY GA INDICATION METHOD
INITIAL DOSAGE
Intial dosage 800 
Mcg
REPEAT 
DOSAGE
400 Mcg
TOTAL 
DOSAGE
IND‐ABO 
INTERVAL
In Hours RESULT ADD INT Side Effects COST{RS} Addl Pro
FAILURE 
EXPULSION TIME
37 INDRANI 22 10699 G1 18 Unwed MISO ONLY 1 4 2400 14 Complete   234
38 KALA 21 10778 G1 16 Unwed MISO ONLY 1 4 2400 13.2 Incomplete IE Vomiting,Bleeding                          234
39 ADHILAKSHMI 24 11006 G2P1L1 18 Unwanted MISO ONLY 1 3 2000 13 Complete   Rigor,Fever                       195 CUT
40 THABASAM 25 11109 G2P1L1 18 UNWAnted MISO ONLY 1 3 2000 13.1 Complete   Vomiting,Diarrhoea                195 CUT
41 REKHA 23 11527 G2P1L1 17 Unwanted MISO ONLY 1 3 2000 11 Complete   Rigor,Fever                       195 CUT
42 ARULSELVI 23 23009 G2P1L1 18 Unwanted MISO ONLY 1 1 1200 7 Complete   Nausea,Vomiting,Pain              117 CUT
43 MEGALA 22 24219 G4P3L3 18 Unwanted MISO ONLY 1 1200 7 Complete   Nausea,Fever                      117
44 VASANTHI 21 24819 G4P3L3 18 ANOMALOUS MISO ONLY 1 1 1200 6.5 Incomplete IE Nausea,Vomiting,Pain              117
45 VIOLA 25 11708 G3P2L2 18 Unwanted MISO ONLY 1 4 2400 19.3 Incomplete IE Bleeding 234
46 SASIKALA 22 11248 G2P1L1 17 Unwanted MISO ONLY 1 4 2400 18.1 Complete   Rigor,Vomiting                    234 CUT
47 MEENA 21 12313 G2P1L1 19 Unwanted MISO ONLY 1 4 2400 16 Complete   234 CUT
48 PODUMPONNU 24 12452 G2P1L1 17 Unwanted MISO ONLY 1 2 1600 9 Complete   Nausea,Pain                       156 CUT
49 DHANALAKSHMI 24 12624 G1 20 Unwed MISO ONLY 1 4 2400 18.1 Complete   Vomiting                          234
50 VALARMATHY 22 12770 G2P1L1 18 Unwanted MISO ONLY 1 4 2400 16.3 Incomplete IE Rigor,Vomiting                    234 CUT
51 KALAIVANI 21 12885 G2P1L1 17 Unwanted MISO ONLY 1 4 2400 15 Complete   234 CUT
52 MARY 24 12917 G2P1L1 16 Unwanted MISO ONLY 1 2 1600 10 Complete   Nausea,Pain                       156
53 VIJAYALAKSHMI 22 13015 G3P2L2 20 Unwanted MISO ONLY 1 4 2400 16.2 Incomplete IE Vomiting                          234
54 ARULMOZHI 24 13270 G3P2L2 20 Unwanted MISO ONLY 1 2 1600 10 Complete   Nausea,Pain                       156 TAT
55 SARANYA 22 13280 G3P2L2 20 Unwanted MISO ONLY 1 2 1600 10 Complete   Nausea,Pain                       156 TAT
56 Vanitha 26 2040 G2P1L1 20 Anamolous Baby MIFE+MISO 1 2 1600 9.5 Complete   Pain                              505 CUT
57 Chinakka 30 2137 G4P3L3 18 Unwanted MIFE+MISO 1 1 1200 6.4 Complete   Nausea,Pain                       466 TAT
58 Jayabarunisha 28 2136 G4P3L3 19 Unwanted MIFE+MISO 1 1 1200 6.3 Complete   Nausea,Vomiting,Pain              466 TAT
59 Manju 27 2677 G5P2L2A2 20 Unwanted MIFE+MISO 1 0 800 5 Complete   Nausea,Pain                       427 TAT
60 RAMESWARI 28 12108 G3P2L2 16 Unwanted MIFE+MISO 1 0 800 5 Complete   Nausea                            427 TAT
61 JAYALAKSHMI 27 18414 G4P3L2 18 Unwanted MIFE+MISO 1 0 800 4 Complete   427
62 KAVITHA 28 19086 G2P1L1 18 ANOMALOUS MIFE+MISO 1 0 800 4 Complete   Nausea                            427 CUT
63 ADHILAKSHMI 28 18724 G3P2L2 18 Unwanted MIFE+MISO 1 1 1200 7.3 Complete   466 TAT
64 VANITHA 28 14078 G2P1L0 18 ANOMALOUS MIFE+MISO 1 2 1600 10 Complete   505
65 GEETHA 26 16619 G3P2L2 19 Unwanted MIFE+MISO 1 3 2000 13 Complete   Rigor,Fever                       544 TAT
66 LAKSHMI 27 19038 G3P2L2 18 Unwanted MIFE+MISO 1 0 800 4.15 Complete   427 TAT
67 GAYATHRI 28 20654 G3P2L2 17 Unwanted MIFE+MISO 1 3 2000 13 Complete   Rigor,Fever                       544 TAT
68 DHANALAKSHMI 28 21490 G3P2L2 20 Unwanted MIFE+MISO 1 0 800 4.2 Complete   427 TAT
69 BHUVANESWARI 29 23279 G3P2L2 19 Unwanted MIFE+MISO 1 0 800 4.3 Complete   Vomiting                          427 TAT
70 LILLY 26 22117 G3P2L2 20 Unwanted MIFE+MISO 1 1 1200 7.2 Complete   466 TAT
71 DEVIKA 28 21961 G3P2L2 19 Unwanted MIFE+MISO 1 1 1200 7.3 Complete   466 TAT
72 SARUMATHI 30 19962 G3P2L2 20 Unwanted MIFE+MISO 1 0 800 4.5 Complete   427 TAT
S. NO NAME
AGE in 
Years InPatient No PARITY GA INDICATION METHOD
INITIAL DOSAGE
Intial dosage 800 
Mcg
REPEAT 
DOSAGE
400 Mcg
TOTAL 
DOSAGE
IND‐ABO 
INTERVAL
In Hours RESULT ADD INT Side Effects COST{RS} Addl Pro
FAILURE 
EXPULSION TIME
73 PREMA 29 19562 G3P2L2 20 Unwanted MIFE+MISO 1 1 1200 7.3 Complete   466
74 SUSEELA 28 11701 G3P2L2 18 Unwanted MISO ONLY 1 4 2400 19.3 Complete   Rigor,Fever                       234
75 JAYALAKSHMI 27 180317 G4P3L2 20 Unwanted MISO ONLY 1 4 2400 FAILURE    MIFE+MISO 234 72hrs
76 PONNI 29 11150 G3P2L2 18 Unwanted MISO ONLY 1 1 1200 8.2 Complete   Nausea,Vomiting,Pain              117
77 SARGUNAVALLI 28 10992 G3P2L2 18 Unwanted MISO ONLY 1 1 1200 7 Complete   Nausea,Pain,Vomiting              117 TAT
78 RUKMANI 28 10956 G3P2L2 18 Unwanted MISO ONLY 1 1 1200 8.3 Complete   Nausea,Pain,Fever                 117
79 BARATHI 27 11526 G3P2L2 18 Unwanted MISO ONLY 1 2 1600 10 Incomplete IE Nausea,Pain                       156
80 SASIKALA 28 11599 G2P1L1 18 Unwanted MISO ONLY 1 3 2000 13 Complete   Pain                              195 CUT
81 SERUMIRA 26 11967 G3P2L2 18 ANOMALOUS MISO ONLY 1 3 2000 12.1 Complete   Rigor,Fever                       195 TAT
82 LAKSHMI 28 23709 G3P2L2 18 Unwanted MISO ONLY 1 2 1600 10 Complete   Nausea,Pain                       156 TAT
83 ESAKIAMAL 28 12501 G3P2L2 20 Unwanted MISO ONLY 1 3 2000 13 Complete   Nausea,Pain                       195 TAT
84 UMA 29 12609 G2P1L1 17 Unwanted MISO ONLY 1 1 1200 7 Complete   Nausea,Pain                       117 CUT
85 RAMEELA 26 12108 G3P2L2 20 Unwanted MISO ONLY 1 3 2000 13 Incomplete IE Rigor,Fever                       195
86 EMARALDMARY 29 13908 G2P1L1 18 Unwanted MISO ONLY 1 4 2400 17 Complete   Fever                             234
87 RAJESWARI 26 13761 G3P2L2 19 Unwanted MISO ONLY 1 4 2400 12.1 Complete   Pain                              234 TAT
88 ASWINI 27 13783 G3P2L2 18 Unwanted MISO ONLY 1 4 2400 FAILURE    MIFE+MISO 234 69 HOURS
89 BARISHA 28 13860 G2P1L1 20 Unwanted MISO ONLY 1 2 1600 10 Incomplete IE Nausea,Pain                       156
90 VIJAYALAKSHMI 26 13756 G3P2L2 20 Unwanted MISO ONLY 1 2 1600 10 Complete   Nausea,Pain                       156
91 KAMATCHI 31 5602 G3P2L2 18 Unwanted MIFE+MISO 1 0 800 4.1 Complete   427 TAT
92 KUTTI 35 17283 G5P4L4 18 Unwanted MIFE+MISO 1 0 800 4.1 Complete   Nausea                            427
93 CHITRA 32 10194 G3P2L2 18 Unwanted MIFE+MISO 1 1 1200 7 Incomplete IE 466
94 KANCHANA 31 22281 G3P2L2 17 Unwanted MIFE+MISO 1 0 800 4.3 Complete   Nausea,Pain                       427 TAT
95 RAJESWARI 32 10618 G3P2L2 20 Unwanted MISO ONLY 1 4 2400 20.3 Complete   Rigor                             234 TAT
96 TAMILARASI 36 10718 G2P1L0 18 ANOMALOUS MISO ONLY 1 3 2000 13 Complete   Vomiting                          195
97 SWEETYMALAR 32 10586 G3P2L2 20 Unwanted MISO ONLY 1 2 1600 9.2 Complete   Nausea,Pain                       156
98 KALA 32 12142 G4P3L3 17 Unwanted MISO ONLY 1 3 2000 13 Incomplete IE 195
99 USHA 32 13301 G2P1L2 18 Unwanted MISO ONLY 1 4 2400 16.5 Incomplete IE 234
100 SHYAMALADEVI 33 13788 G3P2L2 19 Unwanted MISO ONLY 1 4 2400 13.2 Complete   Pain                              234
Key to Master chart
GA Gestational Age
Add Int Additional Intervention
Addl Pro Additional procedure
IE Instrumental evacuation
TAT Transabdominal tubectomy
